Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer

British Journal of Cancer

Volumn 95, Issue 8, 2006, Pages 966-973

  Von Plessen, C ^a   Bergman, B ^b   Andresen, O ^a,f   Bremnes, R M ^c   Sundstrom S ^d   Gilleryd, M ^b   Stephens, R ^e   Vilsvik, J ^d   Aasebo U ^c   Sorenson S ^a,g  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF TROMSØ   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f Fromreide Legesenter ^*  (Norway)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chemotherapy; Non small cell lung cancer; Palliative; Quality of life; Survival; Treatment duration

Indexed keywords

ANTIEMETIC AGENT; BETAMETHASONE; CARBOPLATIN; DEXAMETHASONE; NAVELBINE; ONDANSETRON; TROPISETRON;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; FATIGUE; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NORWAY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PAIN; PATIENT COMPLIANCE; PHLEBITIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE QUESTIONNAIRE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SWEDEN; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PAIN; PALLIATIVE CARE; QUALITY OF LIFE; QUESTIONNAIRES; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VINBLASTINE;

EID: 33750207905     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603383     Document Type: Article

References (49)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376
2. Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C, Bover I, Ruiz-Casado A, Azagra P, Jimenez U, Gonzalez-Larriba JL, Diz P, Cardenal F, Artal A, Carrato A, Morales S, Sanchez JJ, de las Penac R, Felip E, Lopez-Vivanco G (2003) Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21: 3207-3213
3. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Carmichael J (2000) Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 83: 447-453
4. Anonymous (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311: 899-909
5. Anonymous (1997) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15: 2996-3018
6. Ardizzoni AM, Tiseo L, Boni R, Rosell FV, Fossella JH, Schiller M, Paesmans D, Radosavljevic A, Paccagnella P, Mazzanti D, Bisset D (2006) CISCA (cisplatin vs carboplatin) meta-analysis: an individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 24(18S): 7011
7. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A: 635-642
8. Billingham LJ, Bathers S, Burton A, Bryan S, Cullen MH (2002) Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer. Lung Cancer 37: 219-225
9. Braud AC, Levy-Piedbois C, Piedbois P, Piedbois Y, Livartovski A, Le VB, Tredaniel J, Reboul F, Brewer Y, Talbi S, Blanchon F, Paschen B, Durand-Zaleski I (2003) Direct treatment costs for patients with lung cancer from first recurrence to death in France. Pharmacoeconomics 21: 671-679
10. Bremnes RM, Andersen K, Wist EA (1995) Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer 31A: 1955-1959
11. Buccheri GF, Ferrigno D, Curcio A, Vola F, Rosso A (1989) Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer 63: 428-432
12. Cancer Registry of Norway (2005) Cancer in Norway 2003, www. kreftregisteret.no/frame.htm?english.htm
13. Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N (2001) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Health Technol Assess 5: 1-195
14. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17: 3188-3194
15. Delbaldo C, Michiels S, Syz N, Soria JC, Le CT, Pignon JP (2004) Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292: 470-484
16. Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS (2003) Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 138: 639-643
17. Gridelli C, Perrone F, Gallo C (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 91: 66-72
18. Gridelli C, Perrone F, Gallo C, De MF, Ianniello G, Cigolari S, Cariello S, Di CF, D'Aprile M, Rossi A, Migliorino R, Bartolucci R, Bianco AR, Pergola M, Monfardini S (1997) Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur J Cancer 33: 392-397
19. Gridelli C, Perrone F, Ianniello GP, Brancaccio L, Iaffaioli RV, Curcio C, D'Aprile M, Cioffi R, Cigolari S, Rossi A, Palazzolo G, Veltri E, Pergola M, De PS, Gallo C, Monfardini S, Bianco AR (1998) Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole. J Clin Oncol 16: 1414-1419
20. Helsing M, Bergman B, Thaning L, Hero U (1998) Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 34: 1036-1044
21. Hensing TA, Schell MJ, Lee JH, Socinski MA (2005) Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer 47: 253-259
22. Hirose T, Horichi N, Ohmori T, Kusumoto S, Sugiyama T, Shirai T, Ozawa T, Ohnishi T, Adachi M (2005) Patients preferences in chemotherapy for advanced non-small-cell lung cancer. Intern Med 44: 107-113
23. Hutchins LF, Unger JM, Crowley JJ, Coltman Jr CA, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341: 2061-2067
24. Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Murray N, Rapp E (1990) Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 8: 1301-1309
25. King MT (1996) The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5: 555-567
26. Langendijk JA, ten Velde GP, Aaronson NK, de Jong JM, Muller MJ, Wouters EF (2000) Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 47: 149-155
27. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21: 1383-1389
28. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F (1994) Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 106: 861-865
29. Masotti A, Borzellino G, Zannini G, Laterza E, Ricci F, Morandini G (1995) Efficacy and toxicity of vinorelbine-carboplatin combination in the treatment of advanced adenocarcinoma or large-cell carcinoma of the lung. Tumori 81: 112-116
30. Mitchell G, Currow D (2002) Chemotherapy and radiotherapy. When to call it quits. Aust Fam Physician 31: 129-133
31. Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291: 2720-2726
32. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16: 139-144
33. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker Jr S, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353
34. Plessen von C, Aslaksen A (2005) Improving the quality of palliative care for ambulatory patients with lung cancer. BMJ 330: 1309-1313
35. Pocock SJ (1985) Current issues in the design and interpretation of clinical trials. BMJ (Clin Res Ed) 290: 39-42
36. Pronzato P, Ghio E, Losardo PL, Landucci M, Vaira F, Vigani A (1996) Carboplatin and vinorelbine in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 37: 610-612
37. Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T, Thatcher N (2000) Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92: 1074-1080
38. Santomaggio C, Tucci E, Rinaldini M, Algeri R, Righi R, Pepi F, Ghezzi P, Andrei A, Bellezza A (1998) Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: a multicenter phase II study. Am J Clin Oncol 21: 67-71
39. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98
40. Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317: 771-775
41. Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ, Downer SM (1990) Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 300: 1458-1460
42. Smith IE, O'Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, Norton A, Ashley S (2001) Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19: 1336-1343
43. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M, Kies MS (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20: 1335-1343
44. Souquet PJ, Chauvin F, Boissel JP, Bernard JP (1995) Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer. Lung Cancer 12(Suppl 1): S147-S154
45. Spiro SG, Porter JC (2002) Lung cancer - where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 166: 1166-1196
46. Spiro SG, Rudd RM, Souhami RL, Brown J, Fairlamb DJ, Gower NH, Maslove L, Milroy R, Napp V, Parmar MK, Peake MD, Stephens RJ, Thorpe H, Waller DA, West P (2004) Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59: 828-836
47. Stephens RJ, Hopwood P, Girling DJ (1999) Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer 79: 538-544
48. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J (1999) Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 24: 17-24
49. Weynants P, Humblet Y, Jamart J (1997) Additional treatment does not improve the survival of locally advanced or metastatic NSCLC patients who responded after two courses of cisplatin, vindesin, mitomycin chemotherapy. Lung Cancer 18(Suppl): 48